Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 120

1.

Prolonged evolution of the memory B cell response induced by a replicating adenovirus-influenza H5 vaccine.

Matsuda K, Huang J, Zhou T, Sheng Z, Kang BH, Ishida E, Griesman T, Stuccio S, Bolkhovitinov L, Wohlbold TJ, Chromikova V, Cagigi A, Leung K, Andrews S, Cheung CSF, Pullano AA, Plyler J, Soto C, Zhang B, Yang Y, Joyce MG, Tsybovsky Y, Wheatley A, Narpala SR, Guo Y, Darko S, Bailer RT, Poole A, Liang CJ, Smith J, Alexander J, Gurwith M, Migueles SA, Koup RA, Golding H, Khurana S, McDermott AB, Shapiro L, Krammer F, Kwong PD, Connors M.

Sci Immunol. 2019 Apr 19;4(34). pii: eaau2710. doi: 10.1126/sciimmunol.aau2710.

PMID:
31004012
2.

Estimating cholera incidence with cross-sectional serology.

Azman AS, Lessler J, Luquero FJ, Bhuiyan TR, Khan AI, Chowdhury F, Kabir A, Gurwith M, Weil AA, Harris JB, Calderwood SB, Ryan ET, Qadri F, Leung DT.

Sci Transl Med. 2019 Feb 20;11(480). pii: eaau6242. doi: 10.1126/scitranslmed.aau6242.

3.

Age-related immunogenicity and reactogenicity of live oral cholera vaccine CVD 103-HgR in a randomized, controlled clinical trial.

McCarty JM, Lock MD, Bennett S, Hunt KM, Simon JK, Gurwith M.

Vaccine. 2019 Mar 7;37(11):1389-1397. doi: 10.1016/j.vaccine.2019.01.077. Epub 2019 Feb 13.

4.

Defining the interval for monitoring potential adverse events following immunization (AEFIs) after receipt of live viral vectored vaccines.

Kochhar S, Excler JL, Bok K, Gurwith M, McNeil MM, Seligman SJ, Khuri-Bulos N, Klug B, Laderoute M, Robertson JS, Singh V, Chen RT; Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG).

Vaccine. 2018 Nov 26. pii: S0264-410X(18)31235-0. doi: 10.1016/j.vaccine.2018.08.085. [Epub ahead of print]

5.

Lipopolysaccharide-specific memory B cell responses to an attenuated live cholera vaccine are associated with protection against Vibrio cholerae infection.

Haney DJ, Lock MD, Gurwith M, Simon JK, Ishioka G, Cohen MB, Kirkpatrick BD, Lyon CE, Chen WH, Sztein MB, Levine MM, Harris JB.

Vaccine. 2018 May 11;36(20):2768-2773. doi: 10.1016/j.vaccine.2018.04.011. Epub 2018 Apr 11.

6.

Anti-O-specific polysaccharide (OSP) immune responses following vaccination with oral cholera vaccine CVD 103-HgR correlate with protection against cholera after infection with wild-type Vibrio cholerae O1 El Tor Inaba in North American volunteers.

Islam K, Hossain M, Kelly M, Mayo Smith LM, Charles RC, Bhuiyan TR, Kováč P, Xu P, LaRocque RC, Calderwood SB, Simon JK, Chen WH, Haney D, Lock M, Lyon CE, Kirkpatrick BD, Cohen M, Levine MM, Gurwith M, Harris JB, Qadri F, Ryan ET.

PLoS Negl Trop Dis. 2018 Apr 6;12(4):e0006376. doi: 10.1371/journal.pntd.0006376. eCollection 2018 Apr.

7.

Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR in healthy adults age 18-45.

McCarty JM, Lock MD, Hunt KM, Simon JK, Gurwith M.

Vaccine. 2018 Feb 1;36(6):833-840. doi: 10.1016/j.vaccine.2017.12.062. Epub 2018 Jan 6.

8.

Passive Transfer of Immune Sera Induced by a Zika Virus-Like Particle Vaccine Protects AG129 Mice Against Lethal Zika Virus Challenge.

Espinosa D, Mendy J, Manayani D, Vang L, Wang C, Richard T, Guenther B, Aruri J, Avanzini J, Garduno F, Farness P, Gurwith M, Smith J, Harris E, Alexander J.

EBioMedicine. 2018 Jan;27:61-70. doi: 10.1016/j.ebiom.2017.12.010. Epub 2017 Dec 12.

9.

Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge.

Malherbe DC, Mendy J, Vang L, Barnette PT, Reed J, Lakhashe SK, Owuor J, Gach JS, Legasse AW, Axthelm MK, LaBranche CC, Montefiori D, Forthal DN, Park B, Wilson JM, McLinden JH, Xiang J, Stapleton JT, Sacha JB, Haynes BF, Liao HX, Ruprecht RM, Smith J, Gurwith M, Haigwood NL, Alexander J.

J Virol. 2018 Jan 2;92(2). pii: e01092-17. doi: 10.1128/JVI.01092-17. Print 2018 Jan 15.

10.

Randomized, Placebo-Controlled, Double-Blind Phase 2 Trial Comparing the Reactogenicity and Immunogenicity of a Single Standard Dose to Those of a High Dose of CVD 103-HgR Live Attenuated Oral Cholera Vaccine, with Shanchol Inactivated Oral Vaccine as an Open-Label Immunologic Comparator.

Sow SO, Tapia MD, Chen WH, Haidara FC, Kotloff KL, Pasetti MF, Blackwelder WC, Traoré A, Tamboura B, Doumbia M, Diallo F, Coulibaly F, Onwuchekwa U, Kodio M, Tennant SM, Reymann M, Lam DF, Gurwith M, Lock M, Yonker T, Smith J, Simon JK, Levine MM.

Clin Vaccine Immunol. 2017 Dec 5;24(12). pii: e00265-17. doi: 10.1128/CVI.00265-17. Print 2017 Dec.

11.

Antibody-Based Correlates of Protection Against Cholera Analysis of a Challenge Study in a Cholera-Naïve Population.

Haney DJ, Lock MD, Simon JK, Harris J, Gurwith M.

Clin Vaccine Immunol. 2017 May 31. pii: CVI.00098-17. doi: 10.1128/CVI.00098-17. [Epub ahead of print]

12.

PaxVax CVD 103-HgR single-dose live oral cholera vaccine.

Levine MM, Chen WH, Kaper JB, Lock M, Danzig L, Gurwith M.

Expert Rev Vaccines. 2017 Mar;16(3):197-213. doi: 10.1080/14760584.2017.1291348. Review.

PMID:
28165831
13.

The Live Attenuated Cholera Vaccine CVD 103-HgR Primes Responses to the Toxin-Coregulated Pilus Antigen TcpA in Subjects Challenged with Wild-Type Vibrio cholerae.

Mayo-Smith LM, Simon JK, Chen WH, Haney D, Lock M, Lyon CE, Calderwood SB, Kirkpatrick BD, Cohen M, Levine MM, Gurwith M, Harris JB.

Clin Vaccine Immunol. 2017 Jan 5;24(1). pii: e00470-16. doi: 10.1128/CVI.00470-16. Print 2017 Jan.

14.

Unique safety issues associated with virus-vectored vaccines: Potential for and theoretical consequences of recombination with wild type virus strains.

Condit RC, Williamson AL, Sheets R, Seligman SJ, Monath TP, Excler JL, Gurwith M, Bok K, Robertson JS, Kim D, Michael Hendry R, Singh V, Mac LM, Chen RT; Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG).

Vaccine. 2016 Dec 12;34(51):6610-6616. doi: 10.1016/j.vaccine.2016.04.060. Epub 2016 Jun 23. Review.

15.

Adventitious agents and live viral vectored vaccines: Considerations for archiving samples of biological materials for retrospective analysis.

Klug B, Robertson JS, Condit RC, Seligman SJ, Laderoute MP, Sheets R, Williamson AL, Gurwith M, Kochhar S, Chapman L, Carbery B, Mac LM, Chen RT; Brighton Collaboration Viral Vaccine Vector Safety Working Group. Electronic address: brightoncollaborationv3swg@gmail.com.

Vaccine. 2016 Dec 12;34(51):6617-6625. doi: 10.1016/j.vaccine.2016.02.015. Epub 2016 Jun 15. Review.

16.

Single-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection With Vibrio cholerae O1 El Tor.

Chen WH, Cohen MB, Kirkpatrick BD, Brady RC, Galloway D, Gurwith M, Hall RH, Kessler RA, Lock M, Haney D, Lyon CE, Pasetti MF, Simon JK, Szabo F, Tennant S, Levine MM.

Clin Infect Dis. 2016 Jun 1;62(11):1329-1335. doi: 10.1093/cid/ciw145. Epub 2016 Mar 21.

17.

The effect of initiation of antiretroviral therapy on monocyte, endothelial and platelet function in HIV-1 infection.

O'Halloran JA, Dunne E, Gurwith M, Lambert JS, Sheehan GJ, Feeney ER, Pozniak A, Reiss P, Kenny D, Mallon P.

HIV Med. 2015 Nov;16(10):608-19. doi: 10.1111/hiv.12270. Epub 2015 Jun 25.

18.

Oral priming with replicating adenovirus serotype 4 followed by subunit H5N1 vaccine boost promotes antibody affinity maturation and expands H5N1 cross-clade neutralization.

Khurana S, Coyle EM, Manischewitz J, King LR, Ishioka G, Alexander J, Smith J, Gurwith M, Golding H.

PLoS One. 2015 Jan 28;10(1):e0115476. doi: 10.1371/journal.pone.0115476. eCollection 2015.

19.

The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG).

Chen RT, Carbery B, Mac L, Berns KI, Chapman L, Condit RC, Excler JL, Gurwith M, Hendry M, Khan AS, Khuri-Bulos N, Klug B, Robertson JS, Seligman SJ, Sheets R, Williamson AL; V3SWG.

Vaccine. 2015 Jan 1;33(1):73-5. doi: 10.1016/j.vaccine.2014.09.035. Epub 2014 Oct 8.

20.

Age, race/ethnicity, and behavioral risk factors associated with per contact risk of HIV infection among men who have sex with men in the United States.

Scott HM, Vittinghoff E, Irvin R, Sachdev D, Liu A, Gurwith M, Buchbinder SP.

J Acquir Immune Defic Syndr. 2014 Jan 1;65(1):115-21. doi: 10.1097/QAI.0b013e3182a98bae.

21.

Pre-clinical development of a recombinant, replication-competent adenovirus serotype 4 vector vaccine expressing HIV-1 envelope 1086 clade C.

Alexander J, Mendy J, Vang L, Avanzini JB, Garduno F, Manayani DJ, Ishioka G, Farness P, Ping LH, Swanstrom R, Parks R, Liao HX, Haynes BF, Montefiori DC, LaBranche C, Smith J, Gurwith M, Mayall T.

PLoS One. 2013 Dec 3;8(12):e82380. doi: 10.1371/journal.pone.0082380. eCollection 2013.

22.

Managing pulmonary embolism from presentation to extended treatment.

Cohen AT, Dobromirski M, Gurwith MM.

Thromb Res. 2014 Feb;133(2):139-48. doi: 10.1016/j.thromres.2013.09.040. Epub 2013 Oct 14. Review.

PMID:
24182642
23.

Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR, prepared from new master and working cell banks.

Chen WH, Greenberg RN, Pasetti MF, Livio S, Lock M, Gurwith M, Levine MM.

Clin Vaccine Immunol. 2014 Jan;21(1):66-73. doi: 10.1128/CVI.00601-13. Epub 2013 Oct 30.

24.

Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study.

Gurwith M, Lock M, Taylor EM, Ishioka G, Alexander J, Mayall T, Ervin JE, Greenberg RN, Strout C, Treanor JJ, Webby R, Wright PF.

Lancet Infect Dis. 2013 Mar;13(3):238-50. doi: 10.1016/S1473-3099(12)70345-6. Epub 2013 Jan 29.

25.

Thromboprophylaxis in non-surgical cancer patients.

Cohen AT, Gurwith MM, Dobromirski M.

Thromb Res. 2012 Apr;129 Suppl 1:S137-45. doi: 10.1016/S0049-3848(12)70034-8.

PMID:
22682125
26.

High and persistent HIV seroincidence in men who have sex with men across 47 U.S. cities.

Ackers ML, Greenberg AE, Lin CY, Bartholow BN, Goodman AH, Longhi M, Gurwith M.

PLoS One. 2012;7(4):e34972. doi: 10.1371/journal.pone.0034972. Epub 2012 Apr 18.

27.

Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults.

Kennedy JS, Gurwith M, Dekker CL, Frey SE, Edwards KM, Kenner J, Lock M, Empig C, Morikawa S, Saijo M, Yokote H, Karem K, Damon I, Perlroth M, Greenberg RN.

J Infect Dis. 2011 Nov;204(9):1395-402. doi: 10.1093/infdis/jir527. Epub 2011 Sep 15.

28.

Europe's neglected infections of poverty.

Hotez PJ, Gurwith M.

Int J Infect Dis. 2011 Sep;15(9):e611-9. doi: 10.1016/j.ijid.2011.05.006. Epub 2011 Jul 16. Review.

29.

Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine.

Gilbert P, Wang M, Wrin T, Petropoulos C, Gurwith M, Sinangil F, D'Souza P, Rodriguez-Chavez IR, DeCamp A, Giganti M, Berman PW, Self SG, Montefiori DC.

J Infect Dis. 2010 Aug 15;202(4):595-605. doi: 10.1086/654816.

30.

Drug use and the risk of HIV infection amongst injection drug users participating in an HIV vaccine trial in Bangkok, 1999-2003.

Martin M, Vanichseni S, Suntharasamai P, Mock PA, van Griensven F, Pitisuttithum P, Tappero JW, Chiamwongpaet S, Sangkum U, Kitayaporn D, Gurwith M, Choopanya K; Bangkok Vaccine Evaluation Group.

Int J Drug Policy. 2010 Jul;21(4):296-301. doi: 10.1016/j.drugpo.2009.12.002. Epub 2010 Jan 15.

PMID:
20079620
31.

Blood and seminal plasma HIV-1 RNA levels among HIV-1-infected injecting drug users participating in the AIDSVAX B/E efficacy trial in Bangkok, Thailand.

Kittikraisak W, van Griensven F, Martin M, McNicholl J, Gilbert PB, Chuachoowong R, Vanichseni S, Sutthent R, Tappero JW, Mastro TD, Hu DJ, Gurwith M, Kitayaporn D, Sangkum U, Choopanya K.

J Acquir Immune Defic Syndr. 2009 Aug 15;51(5):601-8. doi: 10.1097/QAI.0b013e3181a44700.

32.

Factors associated with incarceration and incident human immunodeficiency virus (HIV) infection among injection drug users participating in an HIV vaccine trial in Bangkok, Thailand, 1999-2003.

Suntharasamai P, Martin M, Vanichseni S, van Griensven F, Mock PA, Pitisuttithum P, Tappero JW, Sangkum U, Kitayaporn D, Gurwith M, Choopanya K; Bangkok Vaccine Evaluation Group.

Addiction. 2009 Feb;104(2):235-42. doi: 10.1111/j.1360-0443.2008.02436.x.

PMID:
19149819
33.

AIDSVAX immunization induces HIV-specific CD8+ T-cell responses in high-risk, HIV-negative volunteers who subsequently acquire HIV infection.

Jones NG, DeCamp A, Gilbert P, Peterson ML, Gurwith M, Cao H.

Vaccine. 2009 Feb 11;27(7):1136-40. doi: 10.1016/j.vaccine.2008.11.071. Epub 2008 Dec 9.

34.

Mucosal HIV-binding antibody and neutralizing activity in high-risk HIV-uninfected female participants in a trial of HIV-vaccine efficacy.

Schneider JA, Alam SA, Ackers M, Parekh B, Chen HY, Graham P, Gurwith M, Mayer K, Novak RM.

J Infect Dis. 2007 Dec 1;196(11):1637-44. Epub 2007 Oct 25.

PMID:
18008247
35.

Response to letter to the editor "Zink TK. Vaccine 2007;25(15):2766-7".

Gorse GJ, Keitel W, Keyserling H, Taylor DN, Lock M, Alves K, Kenner J, Deans L, Gurwith M.

Vaccine. 2007 Oct 16;25(42):7285-7. Epub 2007 Aug 27. No abstract available.

PMID:
17850932
36.

Negative social impacts among volunteers in an HIV vaccine efficacy trial.

Fuchs J, Durham M, McLellan-Lemal E, Vittinghoff E, Colfax G, Gurwith M, Buchbinder S.

J Acquir Immune Defic Syndr. 2007 Nov 1;46(3):362-8.

PMID:
17721399
37.

Mucosal innate immune factors in secretions from high-risk individuals immunized with a bivalent gp120 vaccine.

Cummins JE Jr, Denniston M, Mayer KH, Pickard R, Novak RM, Graham P, Gurwith M, Orelind K, Ackers ML, Dezzutti CS.

AIDS Res Hum Retroviruses. 2007 May;23(5):748-54.

PMID:
17531002
38.

The spread of HIV-1 subtypes B and CRF01_AE among injecting drug users in Bangkok, Thailand.

Xiridou M, van Griensven F, Tappero JW, Martin M, Gurwith M, Vanichseni S, Kittikraisak W, Coutinho R, Choopanya K.

J Acquir Immune Defic Syndr. 2007 Aug 1;45(4):468-75.

PMID:
17496560
39.

Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.

Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, Hu D, Tappero JW, Choopanya K; Bangkok Vaccine Evaluation Group.

J Infect Dis. 2006 Dec 15;194(12):1661-71. Epub 2006 Nov 3.

PMID:
17109337
40.

Comparison of HIV type 1 incidence observed during longitudinal follow-up with incidence estimated by cross-sectional analysis using the BED capture enzyme immunoassay.

McDougal JS, Parekh BS, Peterson ML, Branson BM, Dobbs T, Ackers M, Gurwith M.

AIDS Res Hum Retroviruses. 2006 Oct;22(10):945-52.

PMID:
17067263
41.

LC16m8: an attenuated smallpox vaccine.

Kenner J, Cameron F, Empig C, Jobes DV, Gurwith M.

Vaccine. 2006 Nov 17;24(47-48):7009-22. Epub 2006 Apr 21. Review.

PMID:
17052815
42.
43.

HIV-1 vaccine induced immune responses in newborns of HIV-1 infected mothers.

McFarland EJ, Johnson DC, Muresan P, Fenton T, Tomaras GD, McNamara J, Read JS, Douglas SD, Deville J, Gurwith M, Gurunathan S, Lambert JS.

AIDS. 2006 Jul 13;20(11):1481-9.

PMID:
16847402
44.

Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial.

Gorse GJ, Keitel W, Keyserling H, Taylor DN, Lock M, Alves K, Kenner J, Deans L, Gurwith M.

Vaccine. 2006 Aug 14;24(33-34):5950-9. Epub 2006 Jun 5.

PMID:
16797805
45.

Human immunodeficiency virus (HIV) vaccine trials: a novel assay for differential diagnosis of HIV infections in the face of vaccine-generated antibodies.

Khurana S, Needham J, Mathieson B, Rodriguez-Chavez IR, Catanzaro AT, Bailer RT, Kim J, Polonis V, Cooper DA, Guerin J, Peterson ML, Gurwith M, Nguyen N, Graham BS, Golding H.

J Virol. 2006 Mar;80(5):2092-9.

46.

Highly attenuated smallpox vaccine protects rabbits and mice against pathogenic orthopoxvirus challenge.

Empig C, Kenner JR, Perret-Gentil M, Youree BE, Bell E, Chen A, Gurwith M, Higgins K, Lock M, Rice AD, Schriewer J, Sinangil F, White E, Buller RM, Dermody TS, Isaacs SN, Moyer RW.

Vaccine. 2006 Apr 24;24(17):3686-94.

PMID:
16430997
47.

HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine.

Gilbert PB, Ackers ML, Berman PW, Francis DP, Popovic V, Hu DJ, Heyward WL, Sinangil F, Shepherd BE, Gurwith M.

J Infect Dis. 2005 Sep 15;192(6):974-83. Epub 2005 Aug 12.

PMID:
16107949
48.

Motivations for participating in an HIV vaccine efficacy trial.

Colfax G, Buchbinder S, Vamshidar G, Celum C, McKirnan D, Neidig J, Koblin B, Gurwith M, Bartholow B.

J Acquir Immune Defic Syndr. 2005 Jul 1;39(3):359-64.

PMID:
15980699
49.

Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial.

Gilbert PB, Peterson ML, Follmann D, Hudgens MG, Francis DP, Gurwith M, Heyward WL, Jobes DV, Popovic V, Self SG, Sinangil F, Burke D, Berman PW.

J Infect Dis. 2005 Mar 1;191(5):666-77. Epub 2005 Jan 27.

PMID:
15688279
50.

Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus.

Petri MA, Mease PJ, Merrill JT, Lahita RG, Iannini MJ, Yocum DE, Ginzler EM, Katz RS, Gluck OS, Genovese MC, Van Vollenhoven R, Kalunian KC, Manzi S, Greenwald MW, Buyon JP, Olsen NJ, Schiff MH, Kavanaugh AF, Caldwell JR, Ramsey-Goldman R, St Clair EW, Goldman AL, Egan RM, Polisson RP, Moder KG, Rothfield NF, Spencer RT, Hobbs K, Fessler BJ, Calabrese LH, Moreland LW, Cohen SB, Quarles BJ, Strand V, Gurwith M, Schwartz KE.

Arthritis Rheum. 2004 Sep;50(9):2858-68.

Supplemental Content

Loading ...
Support Center